Form 4: Clene Director Matthew Kiernan Granted Stock Options

Clene Inc. Director Matthew Kiernan was granted 3,720 stock options at an exercise price of $3.60 per share, vesting immediately.

Summary

• Matthew Kiernan, a Director of Clene Inc. (CLNN), was granted stock options.
• The grant occurred on August 14, 2025.
• The options are for 3,720 shares of common stock.
• The exercise price for these options is $3.60 per share.
• The options were granted under the Clene Inc. Amended 2020 Stock Plan.
• The options vest immediately upon grant.
• The options are set to expire on August 13, 2035.

Sentiment

Score: 6

Explanation: The grant of stock options to a director is a standard compensation practice, aligning management's interests with shareholders, which is generally viewed positively.

Positives

• Immediate vesting of the stock options for a director indicates strong alignment of interests with shareholders.
• The grant under an existing stock plan suggests a standard and structured compensation practice.

Future Outlook

NA

Industry Context

This filing details a specific insider transaction and does not provide broader industry context or trends.

Related Party Transactions

• Grant of stock options to Matthew Kiernan, a Director, as part of his compensation under the Clene Inc. Amended 2020 Stock Plan.

Stakeholder Impact

• Shareholders: The grant of stock options to a director aligns their financial interests with the company's stock performance, potentially benefiting shareholders through improved governance and performance incentives.

Key Dates

Recommendation

This Form 4 reports a routine grant of stock options to a director as part of their compensation package. Such grants are common and typically do not provide a strong signal for a 'buy' or 'sell' recommendation, but rather reinforce a 'hold' position as they align management incentives with shareholder value.

Keywords

Clene Inc., CLNN, stock options, insider transaction, Form 4, director compensation, equity grant